Multicentre study with a new biphasic oral contraceptive containing ethinylestradiol and desogestrel. Report on efficacy, cycle control and adverse experiences with special emphasis on blood pressure and weight
Dieben, T.O.; van Beek, A.; Coelingh Bennink, H.J.
Arzneimittel-Forschung 41(9): 996-998
1991
ISSN/ISBN: 0004-4172 PMID: 1839126 Document Number: 317619
In a multicentre study 882 women were treated during a total of 12850 cycles with a new biphasic oral contraceptive: CTR 24. The study period was 18 cycles. The biphasic preparation CTR 24 contains 25 .mu.g desogestrel (CAS 54024-22-5) plus 40 .mu.g ethinylestradiol (CAS 57-63-6) daily for the first 7 days followed by the combination of 125 .mu.g desogestrel and 30 .mu.g ethinylestradiol daily for the subsequent 15 days. One pregnancy occurred. The woman had forgotten one tablet on Day 6 of Cycle 12. The Pearl Index was 0.1 (0.0-0.5) for patient failure. The combination had a good cycle control and only few side effects were reported.